These new drugs might never get a chance to save the U.S. $250 billion By: MarketWatch July 20, 2016 at 09:44 AM EDT Biosimilars are often compared with generics, which have upended drug pricing over the last three decades. Read More >> Related Stocks: AbbVie Amgen Coherus Bio Novartis Ag ADR